Literature DB >> 11592069

High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts.

T Yamamoto1, B Eckes, T Krieg.   

Abstract

Systemic sclerosis (SSc) is a connective tissue disease with unknown etiology characterized by excessive deposition of extracellular matrix in the skin as well as various internal organs. In the early stages of SSc, inflammatory infiltrates of mononuclear cells are found in the dermis, which is associated with increased collagen synthesis produced by activated fibroblasts. Monocyte chemoattractant protein-1 (MCP-1) is a predominant monocyte chemoattractant secreted by a variety of cell types, and recent in vivo and in vitro studies suggest the involvement of MCP-1 in tissue fibrosis. Here we demonstrate that cultured scleroderma fibroblasts, compared to fibroblasts from control skin, spontaneously express significantly elevated MCP-1 levels. Interestingly, exogenously administered MCP-1 stimulated autoinduction of MCP-1 mRNA. This effect was specific to scleroderma fibroblasts and abrogated by actinomycin D. These findings suggest that MCP-1 plays an important role in the induction of scleroderma by MCP-1 release from fibroblasts, which results in recruitment of monocytes to the skin. Moreover, increased responsiveness of scleroderma fibroblasts to MCP-1 could result in a continuation of the fibrotic response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592069     DOI: 10.1002/1521-4141(2001010)31:10<2936::aid-immu2936>3.0.co;2-0

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis.

Authors:  Aniko Rentka; Jolan Harsfalvi; Gabriella Szucs; Zoltan Szekanecz; Peter Szodoray; Krisztina Koroskenyi; Adam Kemeny-Beke
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

2.  Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.

Authors:  Minoru Hasegawa; Manabu Fujimoto; Takashi Matsushita; Yasuhito Hamaguchi; Kazuhiko Takehara; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2010-11-04       Impact factor: 2.980

Review 3.  [Current pathophysiological aspects of systemic sclerosis].

Authors:  T Krieg; N Hunzelmann
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

4.  Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.

Authors:  Minghua Wu; Mesias Pedroza; Robert Lafyatis; Anuh-Teresa George; Maureen D Mayes; Shervin Assassi; Filemon K Tan; Michael B Brenner; Sandeep K Agarwal
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

5.  T cell repertoire in patients with stable scleroderma.

Authors:  K P Tiev; J Abriol; M C Burland; D Antonelli; D Klatzmann; J Cabane; O Boyer
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

6.  Autoimmune mechanisms of scleroderma and a role of oxidative stress.

Authors:  Toshiyuki Yamamoto
Journal:  Self Nonself       Date:  2011-01-01

Review 7.  Chemokines and Their Receptors Are Key Players in the Orchestra That Regulates Wound Healing.

Authors:  Manuela Martins-Green; Melissa Petreaca; Lei Wang
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-09       Impact factor: 4.730

8.  Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts.

Authors:  Carlo Chizzolini; Yann Parel; Agneta Scheja; Jean-Michel Dayer
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 9.  Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis.

Authors:  Alisa E Koch; Oliver Distler
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 10.  Microvascular targets for anti-fibrotic therapeutics.

Authors:  Kai-Ming T Pu; Parid Sava; Anjelica L Gonzalez
Journal:  Yale J Biol Med       Date:  2013-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.